Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendations

Sergio Giralt, Luciano Costa, Jeffrey Schriber, John DiPersio, Richard Maziarz, John McCarty, Paul Shaughnessy, Edward Snyder, William Bensinger, Edward Copelan, Chitra Hosing, Robert Negrin, Finn Bo Petersen, Damiano Rondelli, Robert Soiffer, Helen Leather, Amy Pazzalia, Steven Devine

Research output: Contribution to journalArticle

142 Scopus citations

Abstract

Autologous hematopoietic stem cell transplantation (aHSCT) is a well-established treatment for malignancies such as multiple myeloma (MM) and lymphomas. Various changes in the field over the past decade, including the frequent use of tandem aHSCT in MM, the advent of novel therapies for the treatment of MM and lymphoma, and the addition of new stem cell mobilization techniques, have led to the need to reassess current stem cell mobilization strategies. Mobilization failures with traditional strategies are common and result in delays in treatment and increased cost and resource utilization. Recently, plerixafor-containing strategies have been shown to significantly reduce mobilization failure rates, but the ideal method to maximize stem cell yields and minimize costs associated with collection has not yet been determined. A panel of experts convened to discuss the currently available data on autologous hematopoietic stem cell mobilization and transplantation and to devise guidelines to optimize mobilization strategies. Herein is a summary of their discussion and consensus.

Original languageEnglish (US)
Pages (from-to)295-308
Number of pages14
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number3
DOIs
Publication statusPublished - Mar 2014

    Fingerprint

Keywords

  • Chemomobilization
  • Growth factors
  • Mobilization
  • Mobilization failure
  • Optimal collection
  • Plerixafor

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this